Beacon Therapeutics raises $170M in series B to advance gene therapies for eye disease 09-Jul-2024 By Clara Rodriguez Fernandez The fundraising will accelerate the clinical development of Beacon Therapeutics’ lead gene therapy candidate, which is currently in phase 2/3 trials.